Search results for "burden"

showing 10 items of 393 documents

Large left ventricular metastatis in patient with liposarcoma.

2014

Abstract Metastasis to the heart and pericardium are rare. We present a 44-year-old male with pleural dedifferentiated liposarcoma and multiple metastases, with no previous cardiological history and/or cardiac symptoms. A transthoracic echocardiogram during the advanced stage of disease showed a lobulated, large and mobile mass, with homogeneous echogenicity, attached to the basal posterior wall of the left ventricle via a broad base and with intracavitary growth. This mass extends to inferolateral and inferoseptal wall of the left ventricle.

AdultMalemedicine.medical_specialtyTime FactorsLarge left ventricular metastasiBiopsyHeart VentriclesPleural Neoplasms030204 cardiovascular system & hematologyDoppler echocardiographyLiposarcomaMetastasisHeart Neoplasms03 medical and health sciencesFatal Outcome0302 clinical medicineHumansMedicinePericardium030212 general & internal medicinePleural Neoplasmheart metastases liposarcomamedicine.diagnostic_testbusiness.industryEchogenicityGeneral Medicinemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareEchocardiography DopplerTumor Burdenmedicine.anatomical_structureVentricleliposarcomaDisease Progressioncardiovascular systemRadiologyTransthoracic echocardiogramTomography X-Ray ComputedCardiology and Cardiovascular Medicinebusiness
researchProduct

Dietary exposure in utero and during lactation to a mixture of genistein and an anti-androgen fungicide in a rat mammary carcinogenesis model

2015

Endocrine disruptors may play substantial roles in the high incidence of breast cancer. We previously described how early exposure to the mixture of phytoestrogen genistein (G) and the anti-androgen vinclozolin (V) affects peripubertal mammary development. This study evaluates the carcinogenic potential of exposure to V alone or associated with G from conception until weaning in Wistar rats. Dams were exposed to V, G or GV during pregnancy/lactation. At PND50 offspring were treated with DMBA[7,12-dimethylbenz(a)anthracene]. V or GV maternal exposure decreased number of DMBA-induced mammary tumors in the offspring, without significant modifications in tumor incidence, multiplicity and latenc…

[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionGenisteinDMBAEndocrine DisruptorsToxicologymedicine.disease_causechemistry.chemical_compound0302 clinical medicinePregnancyRisk FactorsLactationVinclozolinOxazoles0303 health sciencesAge Factorsendocrine disruptionGenisteinTumor Burden3. Good health[ SDV.BDLR ] Life Sciences [q-bio]/Reproductive Biologymedicine.anatomical_structuregestational and lactational exposureReceptors EstrogenMaternal ExposureIn utero030220 oncology & carcinogenesisphytoestrogenFemaleReceptors ProgesteroneCarcinoma in Situmedicine.medical_specialtyendocrine systemanti-androgenOffspring910-Dimethyl-12-benzanthraceneBreast NeoplasmsGestational AgeBiologyRisk Assessment03 medical and health sciencesMammary Glands AnimalPrenatal Educationmammary gland carcinogenesisInternal medicinemedicineAnimalsEndocrine systemRats WistarCell Proliferation030304 developmental biologyAndrogen AntagonistsEpithelial Cells[SDV.BDLR]Life Sciences [q-bio]/Reproductive BiologyDietFungicides IndustrialDisease Models AnimalEndocrinologychemistryCarcinogenesis[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
researchProduct

Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990-2019: a systema…

2020

Publisher's version (útgefin grein)

Index (economics)Servicios de SaludSUSTAINABLE DEVELOPMENT GOALS030204 cardiovascular system & hematologyuniversal health coverage; sustaibale develpment goal; global burden of disease; performance;universal health coveragesystematic analysisGlobal Burden of Disease0302 clinical medicineUniversal Health InsuranceRA042111. SustainabilityPer capitaMedical economicsDisease030212 general & internal medicine10. No inequality11 Medical and Health Scienceseffective coverage of health servicesGBD 2019 Universal Health Coverage Collaboratorseducation.field_of_studyPublic healthMedical careSjúkdómar4. Education1. No povertyHealth coveragePublic Health Global Health Social Medicine and EpidemiologyGeneral MedicineHälsovetenskaper3142 Public health care science environmental and occupational healthHealth services3. Good healthGlobal burden of diseaseGlobal Burden of Disease; Health Expenditures; Humans; Universal Health Insurance; World Health OrganizationPurchasing power parityScale (social sciences)/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingLýðheilsauniversal health coveragCANCER SURVIVALACCESSperformanceHumanHeilsuhagfræðimedicine.medical_specialtyHealth coverage GBDGBDUniversal healthGBD 2019Population2019Health expenditures3122 CancersPopulation healthWorld Health Organization03 medical and health sciencesHealth systemsHeilbrigðisvísindiSDG 3 - Good Health and Well-beingGeneral & Internal MedicineDevelopment economicsHealth SciencesmedicineHeilbrigðisstefnasustaibale develpment goalAlþjóðaheilbrigðisstofnuninHumansQUALITYGlobal Burden of Disease StudyeducationPROGRESSDisease burdenPublic healthHealth services accessibilityCAREHeilbrigðisþjónusta//purl.org/pe-repo/ocde/ford#3.02.00 [https]Health ExpenditureFolkhälsovetenskap global hälsa socialmedicin och epidemiologi3121 General medicine internal medicine and other clinical medicineMorbilityAdministración de los Servicios de SaludMedical policyBusinessHealth ExpendituresHeilbrigðiskerfi
researchProduct

Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease

2017

BackgroundSorafenib is the recommended treatment for advanced hepatocellular carcinoma (HCC), but transarterial chemoembolization (TACE) is performed in individual cases with limited extrahepatic spread. The aim of this study was to compare the outcome of patients with HCC and extrahepatic disease (EHD) treated with sorafenib and TACE.MethodsA total of 172 patients with HCC and EHD treated with sorafenib (n = 98) or TACE (n = 74) at three German referral centers (Hannover, Mainz and Hamburg) were included in this study. In order to reduce selection bias, patients were matched for significant demographic differences using a propensity score analysis.ResultsPatients with liver cirrhosis, high…

OncologySorafenibmedicine.medical_specialtyCirrhosisTumor burdenDiseaseGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinemedicineOverall survivalIn patientneoplasmsbusiness.industryGastroenterologyOriginal Articlesmedicine.diseasedigestive system diseasesOncology030220 oncology & carcinogenesisHepatocellular carcinomaPropensity score matching030211 gastroenterology & hepatologybusinessmedicine.drugUnited European Gastroenterology Journal
researchProduct

Association between toenail scandium levels and risk of acute myocardial infarction in European men: the EURAMIC and Heavy Metals Study

2002

The association between scandium status and risk of acute myocardial infarction (MI) was examined in a multicentre case control study in 10 centres from Europe and Israel. Scandium in toenails was assessed in 684 cases and 724 controls less than 70 years of age. Mean concentrations of toenail scandium were 6.74 micro/kg in cases and 7.75 microg/kg in controls. Scandium among controls, adjusted for age and centre was positively associated with concentrations of lycopene and oleic acid in adipose tissue (P = 0.002 for both nutrients). Pearson correlations adjusted for age and centre were significant (P0.05) between scandium and lycopene (r = 0.08), zinc (r = 0.08), mercury (r = 0.18) and olei…

Male0301 basic medicinetissue levelcorrelation analysisHealth Toxicology and MutagenesisscandiumMyocardial Infarction010501 environmental sciencesalpha tocopherolToxicology01 natural sciencesGastroenterologychemistry.chemical_compoundLycopeneRisk Factorsmetal recoveryScandiumMyocardial infarctionFamily historyseleniumRare earth elementsbeta carotenefamily historyadultarticlerisk assessmentMiddle AgedLycopeneadipose tissueHeavy metalsHealthdiabetes mellitusBiological MarkersAntioxidantRisk assessmentcardiovascular riskmedicine.medical_specialtymercuryhypertensiontoealcohol consumptionchemistry.chemical_elementPhysiological Sciencessmokingheart protectioncoronary risk03 medical and health sciencesInternal medicineDiabetes mellitusmedicineHumanscontrolled studyhuman0105 earth and related environmental sciences030102 biochemistry & molecular biologybusiness.industryPublic Health Environmental and Occupational HealthCase-control studyheavy metalcase control studymedicine.diseasemajor clinical studybody massbody burdenSurgeryacute heart infarctionoleic acidNailschemistryCase-Control Studiesalpha-TocopherolbusinessScandiumBiomarkersToxicology and Industrial Health
researchProduct

Development and validation of the mastocytosis quality of life questionnaire: MC-QoL

2016

Background Mastocytosis is a heterogeneous disease characterized by a clonal expansion of mast cells in various organs. The vast majority of patients affected suffer from signs and symptoms caused by mediator release from mast cells. Although the disease burden is high, there is currently no specific instrument to measure health-related quality of life (HRQoL) impairment in patients with mastocytosis. Objective The aim of this study was to develop and validate a disease-specific tool to assess HRQoL impairment in patients with cutaneous and indolent systemic mastocytosis, the Mastocytosis Quality of Life Questionnaire (MC-QoL). Methods Sixty-two potential MC-QoL items were developed in a co…

AdultMalemedicine.medical_specialtyPathologyAdolescentImmunologyDiseaseMediator releaseYoung Adult030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineQuality of lifeSurveys and QuestionnairesInternal medicinemedicineHumansImmunology and AllergyIn patientSystemic mastocytosisDisease burdenAgedFace validityAged 80 and overbusiness.industryReproducibility of ResultsMiddle Agedmedicine.diseasehumanitiesCombined approach030228 respiratory systemPopulation SurveillanceQuality of LifeFemaleFactor Analysis StatisticalbusinessMastocytosisAllergy
researchProduct

The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017 : a systematic analysis for the Global Bu…

2020

Background\ud \ud Cirrhosis and other chronic liver diseases (collectively referred to as cirrhosis in this paper) are a major cause of morbidity and mortality globally, although the burden and underlying causes differ across locations and demographic groups. We report on results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 on the burden of cirrhosis and its trends since 1990, by cause, sex, and age, for 195 countries and territories.\ud \ud \ud \ud Methods\ud \ud We used data from vital registrations, vital registration samples, and verbal autopsies to estimate mortality. We modelled prevalence of total, compensated, and decompensated cirrhosis on the bas…

Liver CirrhosisMaleCirrhosisCost-Benefit AnalysisHEPATITIS-BGlobal Burden of DiseaseLiver diseaseDisability Evaluation0302 clinical medicineBurden Global Mortality CirrhosisNon-alcoholic Fatty Liver DiseaseRisk FactorsFIBROSISEurope EasternPOPULATIONAged 80 and overeducation.field_of_studySingaporeMortality rate1. No povertyGastroenterologyHepatitis CHepatitis BMiddle AgedHepatitis BHepatitis C3. Good healthPREVALENCE030220 oncology & carcinogenesisAsia Central030211 gastroenterology & hepatologyEgyptFemaleQuality-Adjusted Life YearsViral hepatitisLife Sciences & BiomedicineAdultEUROPEPopulationGBD 2017 Cirrhosis CollaboratorsArticle03 medical and health sciencesLIVER-DISEASEmedicineHumanseducationLiver Diseases AlcoholicAfrica South of the SaharaAgedScience & TechnologyHepatologyGastroenterology & Hepatologybusiness.industryMORTALITYDISABILITYDECOMPENSATIONmedicine.diseaseYears of potential life lostEarly DiagnosisSocioeconomic Factors3121 General medicine internal medicine and other clinical medicineINJURIESHuman medicinebusinessDemographyRCLancet gastroenterology & hepatology
researchProduct

2015

Quality of life (QoL) is increasingly recognized as central to the broad construct of recovery in patients with substance use disorders (SUD). However, few longitudinal studies have evaluated changes in QoL after SUD treatment and included patients with SUD that were compulsorily hospitalized. This study aimed to describe QoL among in-patients admitted either voluntarily or compulsorily to hospitalization and to examine patterns and predictors of QoL at admission and at 6 months post treatment. This prospective study followed 202 hospitalized patients with SUD that were admitted voluntarily (N=137) or compulsorily (N=65). A generic QoL questionnaire (QoL-5) was used to assess QoL domains. R…

medicine.medical_specialtybusiness.industryPublic Health Environmental and Occupational HealthSymptom burdenGeneral Medicinemedicine.diseasehumanitiesConfidence intervalSubstance abuseQuality of lifePhysical therapyMedicineIn patientSubstance usePost treatmentbusinessProspective cohort studyHealth and Quality of Life Outcomes
researchProduct

β-Catenin Contributes to Lung Tumor Development Induced by EGFR Mutations

2014

Abstract The discovery of somatic mutations in EGFR and development of EGFR tyrosine kinase inhibitors (TKI) have revolutionized treatment for lung cancer. However, resistance to TKIs emerges in almost all patients and currently no effective treatment is available. Here, we show that β-catenin is essential for development of EGFR-mutated lung cancers. β-Catenin was upregulated and activated in EGFR-mutated cells. Mutant EGFR preferentially bound to and tyrosine phosphorylated β-catenin, leading to an increase in β-catenin–mediated transactivation, particularly in cells harboring the gefitinib/erlotinib-resistant gatekeeper EGFR-T790M mutation. Pharmacologic inhibition of β-catenin suppresse…

Cancer ResearchLung NeoplasmsCarcinogenesisAfatinibMutation MissenseAntineoplastic AgentsMice TransgenicAfatinibmedicine.disease_causeArticleTransactivationGefitinibCarcinoma Non-Small-Cell LungCell Line TumormedicineAnimalsHumansEpidermal growth factor receptorLung cancerbeta CateninMutationbiologyProtein Stabilitymedicine.diseaseXenograft Model Antitumor AssaysTumor BurdenUp-Regulationrespiratory tract diseasesErbB ReceptorsGene Expression Regulation NeoplasticHEK293 CellsOncologyDoxycyclineCateninImmunologyQuinazolinesCancer researchbiology.proteinCarcinogenesismedicine.drugCancer Research
researchProduct

Trends in Prevalence of Blindness and Distance and Near Vision Impairment Over 30 Years and Contribution to the Global Burden of Disease in 2020

2020

Background: The Vision Loss Expert Group and Global Burden of Disease Study have extensively updated estimates of global vision loss burden in 2020, temporal changeover 3 decades and forecasts for 2050. Methods: A systematic review and meta-analysis was conducted of population-based datasets relevant to vision impairment (VI) from January 1980 to October 2018. Hierarchical models were fitted to estimate 2020 prevalence (with 95% uncertainty intervals, UI) of (1) mild VI (presenting visual acuity [PVA] 6/12). Findings: In 2020, an estimated 43.2 million (95% UI: 37.5-48.2 million; 55% female) people were blind, 295.3 (95% UI 267.0-325.5) million had MSVI, 257.3 (95% UI 232.2-284.7) million h…

Burden of diseasemedicine.medical_specialtyeducation.field_of_studyVisual acuityBlindnessbusiness.industryPopulationGlobal visionmedicine.diseaseExpert groupNear visionEpidemiologyMedicinemedicine.symptombusinesseducationDemographySSRN Electronic Journal
researchProduct